SC 13G/A: Replimune Group, Inc.

AI Summary

SC 13G/A filing by Replimune Group, Inc..

Risk Assessment

Risk Level: low

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $0.0001 — to Common Stock at an exercise price of $0.0001 per share with no expiration date (the
• $0.0001 M — he outstanding Common Stock (the “$0.0001 Maximum Percentage”). By written no
• $0.001 M — he outstanding Common Stock (the “$0.001 Maximum Percentage”). By written no

Filing Documents

• tm2426483d10_sc13ga.htm (SC 13G/A) — 82KB
• 0001104659-24-118977.txt ( ) — 84KB

(a)

Item 1(a) Name of Issuer: Replimune Group, Inc. (the “Issuer”)

(b)

Item 1(b) Address of Issuer’s Principal Executive Offices: 500 Unicorn Park Drive, Suite 303 Woburn, MA 01801

(a)

Item 2(a) Name of Person Filing: This Amendment No. 2 is being filed jointly by the Reporting Persons.

(b)

Item 2(b) Address of Principal Business Office or, if None, Residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690

(c)

Item 2(c) Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

(d)

Item 2(d) Title of Class of Securities: Common Stock, $0.001 par value per share (“Common Stock”)

(e)

Item 2(e) CUSIP Number: 76029N106 Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act. (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act. (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act. (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4 Ownership: Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 2 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock of the Issuer directly held by each of 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Funds”), which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as shares of Common Stock that may be acquired upon the exercise of the Prefunded Warrants (as defined below), subject to the limitations on exercise described below. The information set forth below is based upon 68,321,396 shares of Common Stock outstanding as of August 5, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024. Such percentage figures are calculated in accordance with Rule 13d-3 under t